Health Condition 1: F322- Major depressive disorder, singleepisode, severe without psychotic features Health Condition 2: null- treatment resistant depression
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Age range 18-60 years 2.Male and Female 3.Written informed consent. 4.Presence of Major Depressive Disorder as per DSM V guidelines 5.Refractory to at least two anti-depressant medications
Exclusion criteria
Exclusion criteria: 1. Co-morbid psychiatric diagnoses such as psychosis, bipolar disorder, substance dependence (including nicotine dependence) 2. Mental retardation, neurological disorders and severe medical illness 3. pregnancy or breast feeding 4.Diagnosis of major depressive disorder with psychotic features during the current depressive episode 5.allergy to ketamine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient reported response to treatment [ Time Frame: Acute Study Phase (Baseline Visit to End of Treatment Visit) - approximately 2-3 weeks ] Response is defined as at least a 50% improvement in Baseline QIDS-SR-16 score at End of Treatment Visit. The End of Treatment Visit will occur 3-5 weeks after the Baseline Visit. Timepoint: baseline and 2-3 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| clinician reported response to treatment [ Time Frame: Acute Study Phase (Baseline Visit to End of Treatment Visit) - approximately 3-5 weeks ] Number of patients with an improvement in their Baseline MADRS score at the End of Treatment Visit. The End of Treatment Visit will occur 2-3 weeks after the Baseline Visit. Timepoint: baseline and 2-3 weeks | — |
Countries
India
Contacts
Ahana hospitals